SOMther (lutetium-177 DOTA satoreotide) / Ariceum Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SOMther (lutetium-177 DOTA satoreotide) / Ariceum Therap
NCT03773133: Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

Terminated
1/2
9
Europe, US
Satoreotide tetraxetan, 177Lu-OPS201, Satoreotide trizoxetan, 68Ga-OPS202
Ipsen
Small Cell Lung Cancer and Breast Cancer
10/19
10/19
2020-003640-88: A long-term safety surveillance study in participants previously treated with 177Lu-IPN01072

Not yet recruiting
1/2
38
Europe
177Lu-satoreotide tetraxetan, 177Lu-SSO110, 177Lu-IPN01072,177Lu-OPS201, Solution for injection
Ariceum Therapeutics GmbH, Ariceum Therapeutics GmbH
Neuroendocrine tumors (NETs), Neuroendocrine tumors (NETs), neoplasms that arise from cells of the endocrine (hormonal) and nervous systems., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
 
 
NCT02592707 / 2015-002867-41: Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Terminated
1/2
40
Europe, Canada, US, RoW
Satoreotide tetraxetan, 177Lu-OPS201, 177Lu-IPN01072, Amino acid solution, OPS301, IPN60070, Arginine and lysine, Antiemetic, Dexamethasone, Ondansetron
Ipsen
Neuroendocrine Tumors
02/22
02/22

Download Options